Companies / Akeso
Akeso Pipeline
CompanyAkeso, Inc. is a Chinese biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing antibody drugs. Established in 2012, it listed on the Hong Kong Stock Exchange in 2020 under stock code 9926. The company reports a pipeline across oncology, autoimmune, inflammation, and metabolic diseases.
Continuously tracked·last revised
Data: CSV·JSON·Browse the trials
Follow Akeso
Email me when this page changes — new trials, changes of phase or status, and results as they are posted.
No mail is going out yet — your address is recorded now, used for nothing else, and never shared.
Thanks — your request is recorded. No mail is sent yet.
That did not work. Check the address and try again.
Recruiting Phase 3
Recently started
| Trial | Phase | Status | Sponsor | Started |
|---|---|---|---|---|
| Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma NCT07700979 | Phase 3 | Recruiting | Akeso | Started 2026-09 |
| A Study of AK157D1 for Injection in Advanced Solid Tumors NCT07847281 | Phase 1 | Not yet recruiting | Akeso | Started 2026-09 |
| A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps NCT07755371 | Phase 2 | Not yet recruiting | Akeso | Started 2026-08 |
| A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer NCT07591090 | Phase 2 | Recruiting | Akeso | Started 2026-07 |
| A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer NCT07669779 | Phase 2 | Recruiting | Akeso | Started 2026-07 |
Pipeline
Phase by status
| Phase | Recruiting | Not yet | Active | Completed | Terminated | Unknown | Total |
|---|---|---|---|---|---|---|---|
| Phase 1 | 7 | 9 | 1 | 12 | — | 3 | 32 |
| Phase 1/2 | 8 | 4 | 7 | 14 | 4 | — | 37 |
| Phase 2 | 11 | 8 | 5 | 22 | 3 | — | 49 |
| Phase 3 | 13 | 3 | 7 | 9 | 1 | 2 | 35 |
| Unknown | 1 | — | — | — | — | — | 1 |
Trials started per year
Conditions studied, by phase
| Condition | Phase 1 | Phase 1/2 | Phase 2 | Phase 3 | Unknown | Total |
|---|---|---|---|---|---|---|
| Carcinoma, Hepatocellular | — | 2 | 5 | 2 | — | 9 |
| Carcinoma, Non-Small-Cell Lung | — | 2 | 1 | 5 | — | 8 |
| Dermatitis, Atopic | — | 1 | 3 | 2 | — | 6 |
| Uterine Cervical Neoplasms | — | — | 4 | 1 | — | 5 |
| Nasopharyngeal Carcinoma | — | — | 3 | 1 | — | 4 |
| Pancreatic Neoplasms | 1 | — | 2 | 1 | — | 4 |
| Psoriasis | 1 | — | 2 | 1 | — | 4 |
| Hypercholesterolemia | 1 | — | 2 | — | — | 3 |
| Hyperlipidemias | — | — | — | 3 | — | 3 |
| Neoplasms | 2 | 1 | — | — | — | 3 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Akeso | 154 | 35 |
Frequent collaborators
| # | Collaborator | Trials |
|---|---|---|
| 1 | Akeso Pharmaceuticals, Inc. | 7 |
| 2 | Akeso Tiancheng, Inc | 7 |
| 3 | AD Pharmaceuticals Co., Ltd. | 4 |
| 4 | AD Pharma (Guangdong) | 1 |
| 5 | Akesobio Australia Pty Ltd | 1 |
| 6 | Chipscreen Biosciences, Ltd. | 1 |
| 7 | Fudan University | 1 |
| 8 | Peking University Cancer Hospital & Institute | 1 |
| 9 | Shanghai Virogin Biotech Co., Ltd. | 1 |
| 10 | Summit Therapeutics | 1 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Carboplatin | 19 |
| 2 | Paclitaxel | 14 |
| 3 | Cisplatin | 11 |
| 4 | Oxaliplatin | 10 |
| 5 | Fluorouracil | 9 |
| 6 | Injections | 8 |
| 7 | Pemetrexed | 8 |
| 8 | Docetaxel | 7 |
| 9 | Gemcitabine | 7 |
| 10 | Capecitabine | 6 |
Terminations
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT05932212 Terminated | Terminated | Sponsor decision | 2026-05-31 |
| NCT05636267 Terminated | Terminated | Terminated due to sponsor strategic development reprioritization. | 2025-04-15 |
| NCT05559541 Terminated | Terminated | Development strategy adjustment | 2024-05-31 |
| NCT03866980 Terminated | Terminated | corporate strategy adjustment | 2023-12-31 |
| NCT04444141 Terminated | Terminated | Due to difficuty of erollment and consideration of clinical guideline,The sponsor decided to stop study. | 2022-09-30 |
| NCT04547101 Terminated | Terminated | Due to difficuty of erollment and consideration of clinical guideline,The sponsor decided to stop study. | 2022-09-30 |
| NCT05155020 Terminated | Terminated | The clinical development strategy has been changed | 2022-08-05 |
| NCT04999605 Terminated | Terminated | Too low inclusion rate | 2022-06-10 |
Evidence
- Results reported
- 0%0 of 57 completed
- Published
- 0%0 of 57 completed
Trial profile
- Median enrollment
- 134
- Median duration
- 33.8months
- Countries
- 8
- Study sites
- 666
Who is enrolled
Median enrollment by phase
- Phase 1
- 79
- Phase 1/2
- 128
- Phase 2
- 100
- Phase 3
- 469
- Unknown
- 610
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Beijing | China | 51 |
| 2 | Shanghai | China | 48 |
| 3 | Guangzhou | China | 34 |
| 4 | Hangzhou | China | 32 |
| 5 | Changsha | China | 22 |
| 6 | Tianjin | China | 20 |
| 7 | Wuhan | China | 19 |
| 8 | Chengdu | China | 14 |
| 9 | Jinan | China | 14 |
| 10 | Fuzhou | China | 13 |